Cloudbreak Pharma is an innovative ophthalmic drug company and leader in ocular R&D, based in Irvine, California.

We are dedicated to developing first-in-class and best-in-class ophthalmic drugs, leveraging our proprietary Multi-Kinase Inhibitors (MKI) platform. Our lead asset, the eye drop CBT-001, is currently in mid-Phase 3 clinical trials for pterygium, a condition affecting millions globally. CBT-004 is also progressing into Phase 3 for pinguecula, offering the potential for the first and only FDA-approved therapies for these significant unmet needs.

Cloudbreak Pharma’s team comprises experienced ophthalmologic scientists and business professionals, committed to bringing innovative treatments from pre-clinical development to NDA approval. We’ve established strategic partnerships with Santen Pharmaceutical and Grand Pharma to expand our reach and commercialization efforts across key regions, including Japan, China, Hong Kong, Taiwan, and Southeast Asia. Our mission is to ‘Seeing Life Better, Through Medicine.’

CBT-001 | Cloudbreak Pharma, Inc.

Product description

Cloudbreak Pharma, Inc. Irvine, United States (US)

Price: N/A

Cloudbreak Pharma, Inc.
Irvine, United States (US)